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SHOULD NEITHER SCLEROTHERAPY NOR
PROPRANOLOL BE USED PROPHYLACTICALLY
FOR OESOPHAGEAL VARICES?
ABSTRACT
The PROVA Study Group. (1991) Prophylaxis offirst hemorrhagefrom esophageal
oarices by sclerotherapy, propranolol or both in cirrhotic patients: A randomized
multicenter trial. Hepatology; 14, 1016-1024
The objective of this randomized multicenter trial was to assess the prophylactic
effect on the incidence and severity of the first variceal hemorrhage of endoscopic
sclerotherapy, propranolol and the combination of the two compared with none of
these treatments in patients with cirrhosis and esophageal varices. Among 819
cirrhotic patients who never had experienced variceal bleeding, esophagoscopy
revealed varices in 379, ofwhom 286 were enrolled in the trial; 73 were allocated to
sclerotherapy (paravenous polidocanoi [10 mg/mi] every 1 to 2 wk until eradication),
68 to propranolol (slow-release preparation in one daily dose adjusted to provide
about 25% heart rate reduction), 73 to both treatments and 72 to neither of the two
treatments. The patients were observed for up to 42 months, with an ,average of 15
months. After variceal bleeding, patients in all groups received sclerotherapy only.
The incidences of variceal bleeding (n 50) were almost identical in the four
groups. The relative risk (with 95% confidence limits) with sclerotherapy was 1.06
(0.61 to 1.84), and the relative risk with propranolol was 0.92 (0.53 to 1.60). The
mortality rate after variceal bleeding (n 29) did not differ significantly either. The
mortality rate without variceal bleeding (n 46) was 2.75 (1.45 to 5.22) times
higher in the sclerotherapy groups than in the nonsclerotherapy groups (p 0.002),
whereas propranolol showed no effect, the relative risk being 1.17 (0.66 to 2.10). The
total mortality rate showed no significant difference between the sclerotherapy,
propranolol and control groups, but the combined therapy group had a significantly
increased mortality rate.
This trial yielded evidence against prophylaxis of variceal hemorrhage in cirrhosis
by endoscopic sclerosing injections, with or without propranolol and no support of
propranolol used alone. (Hepatology 1991; 14:000-000.)HPB INTERNATIONAL 135
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This is a Danish study from the PROVA study group, which compares endoscopic
sclerotherapy, propranolol, the combination of the two and a control group for the
prevention and effect on severity of the first variceal haemorrhage. Previous studies
of prophylactic sclerotherapy have shown discordant results, most showing no
benefit or harmful effects 1. In contrast previous propranolol and nadolol studies
have shown benefit of beta-blockers. Most of these trials selected patients with
large varices, now known to represent those patients with an increased risk of
bleeding from varices for the first time. In the present study amongst 819 cirrhotics
without bleeding, 379 had varices 286 of whom were randomized irrespective of
variceal size. Allocation was: sclerotherapy (paravariceal 1% polidocanol) n 73,
propranolol (slow release, one daily dose, adjusted to provide 25% heart rate
reduction) n 68, both treatments n 73 and none 72. The average follow up was
15 months with a maximum of 42 months. Injections were carried out at 1 to 2 week
intervals until eradication with 3 monthly endoscopy thereafter. Propranolol was
given in incremental doses of 80 mg, providing the pulse remained above 50 per
minute and blood-pressure above 90 mmHg. Thus sclerotherapy and propranolol
were administered using presently accepted regimens.
The study is well designed and analyzed. The authors had estimated that a
sample size of 440 patients would be necessary if interaction between treatments
was to occur, but only 220 patients if no interaction could be demonstrated. The
assumption was a 50% reduction in the rate of first bleeding would occur with
prophylactic treatment (with a baseline annual rate of bleeding of 25%), with a
type 1 error of 5% and type 2 of 20%. The trial was stopped following the results of
the planned interim analysis at 3 years because of excess mortality in the sclerother-
apy treated patients.
Variceal bleeding occurred in a similar proportion in all groups" sclerotherapy
versus none- relative risk 1.06 (0.61 1.84, 95% confidence limits) and propranolol
versus none 0.92 (0.53 1.6, 95% C.I.). The bleeding rate in controls was 15%
comparable to that seen in the control groups of previous studies where the
majority of patients had larger varices. Thus, it is unlikely that the prophylactic
treatments were given to patients who were less at risk of bleeding compared to
other trials. Variceal bleeding was defined as that requiring transfusion and which
by endoscopy the source, was considered to be varices.
Thus bleeding not requiring transfusion was not considered a bleeding episode
and neither was bleeding within 24 hours of sclerotherapy, so that there was a bias
towards favouring sclerotherapy as three patients had this type of bleeding. In
contrast there was only one minor bleed in the control group and one in the
propranolol group. In addition there was more non-variceal bleeding in the
sclerotherapy groups: 14 (12 needing transfusion) in the injected group; 9 (7
needing transfusion) in the combined group; 11 (7 needing transfusion) in the
propranolol group; and 6 (4 needing transfusion) in the control group.
The mortality rate after variceal bleeding was the same, but the mortality without136 HPB INTERNATIONAL
variceal bleeding was 2.75 times higher, 95% confidence limits (1.45-5.22) in the
sclerotherapy groups compared to the non-sclerotherapy groups (p 0.002), wher-
eas propranolol had no effect. The total mortality rate was increased in the
combined treatment group. This was confirmed when co-variables with an indepen-
dent predictive value for mortality were assessed. This necessitated stopping the
trial early. This effect of sclerotherapy was also seen in the Veterans
Administration trial in the USA3, in which the increased mortality seen with
sclerotherapy, was not due to an increase in bleeding-related deaths, and in which
the excess mortality disappeared once sclerotherapy was stopped. This trial was
also stopped early.
In this Danish study sclerotherapy achieved eradication of varices in 66% of the
group who only had injection, and in 67% of the combined treatment group. These
figures are comparable to other trials and do not suggest an "aggressive" sclerother-
apy programme which could be directly implicated in causing the excess deaths.
Moreover, although complications of sclerotherapy were frequent these did not
contribute to the mortality: oesophageal stricture (n= 10), ulceration (n=9),
mediastinitis and septicaemia (n 1), aphonia (n 1), recurrent pulmonary emboli
(n= 1) and a perforation without sequelae (n= 1). In the propranolol group:
dizziness (n 9), cold extremities (n 8), hypotension (n 7), bradycardia (n 4),
orthostatic hypotension (n 3), heart failure (n 3), fatigue (n 3), nightmares
(n=2), asthma (n=3), acute cardiac failure (n=l). These complications are
similar to other beta-blocker trials. Discontinuation of propranolol occurred in only
19% of the group treated with drug alone (n 7 side effects, n 5 withdrawal) and
13% (n 3 side effects, n 5 withdrawal) of the combined group again similar to
previous trials. These two aspects of beta-blockade do not suggest that the drug
treatment groups had a more favourable response than in other trials, thus
potentially accentuating the differences between beta-blockers and sclerotherapy.
Moreover, these aspects do not explain the lack of therapeutic efficacy of proprano-
lol seen in this trial.
The authors comment that their results with propranolol are compatible with the
range of effect evidenced from an updated meta-analysis of beta-blocker trials4.
Thus the different result may simply be due to random sampling variation. The
overviews of sclerotherapy and beta-blockers trialsTM show that beta-blockers do
significantly reduce the risk of first bleeding from varices, with a borderline effect
on survival. No beta-blocker trial has a significantly increased mortality. In contrast
the sclerotherapy trials show statistical heterogeneity in the meta-analysis. Some of
the largest trials show an increased mortality in the sclerotherapy groups. This
meta-analytical data, re-enforced by this trial, indicate that sclerotherapy should
not be used for the primary prophylaxis of variceal bleeding and that beta-blockers
do no harm and are likely to be beneficial. They are the treatment of choice. The
reasons for the excess mortality in the sclerotherapy treated patients are not clear,
but this raises the issue of whether it may occur in patients whose varices are
injected for the prevention of variceal re-bleeding.
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EFFECT OF ALCOHOL CONSUMPTION ON
VARICEAL REBLEEDING AND MORTALITY
ABSTRACT
McCormick, P.A., Morgan, M.Y., Phillips, A., Yin, T.P., Mclntyre, N. and
Burroughs, A.K. (1992) The effects of alcohol use on rebleeding and mortality in
patients with alcoholic cirrhosis following oariceal haemorrhage. Journal of
Hepatology; 14, 99-103.
The effect of continued alcohol intake on prognosis in alcoholic cirrhotics who have
already bled from varices is controversial. To investigate the effect of alcohol intake
on prognosis we studied 189 consecutive alcoholic cirrhotics admitted, for the first
time, to the Royal Free Hospital with variceal bleeding. Sixty-six died within 30 days
of admission and 23 were excluded from the study for other reasons. Of the 100
remaining 15 remained ’probably abstinent’ over long-term follow-up, 29 drank
occasionally and 56 continued to misuse/abuse alcohol. The percentage survival
probability at 2 years was 66% in the probable abstainers, 68% in the occasional
drinkers and 63% in the alcohol abuse/misuse group. There were no significant
differences in either mortality or rebleeding rates between the three groups. A
rebleeding index (designed to take account of the number of rebleeds per patient and
the total length of follow-up) also failed to show any significant difference between
the three groups. The Cox proportional hazard model was used to study the effect of
the following factors on rebleeding and mortality; age, sex, alcohol use, Pugh’s
score, acute treatment received for initial variceal bleed and long-term treatment
received for prevention of recurrent variceal haemorrhage. Pugh’s score was
significantly related to risk of death during follow-up (p 0.0122), but none of the
others factors was significantly related to risk of rebleeding or mortality. Using
conventional methods to determine alcohol use we were unable to demonstrate
significant effects of alcohol intake on rebleeding or mortality in alcoholic cirrhotics
who had bled from oesophageal varices.